Pharmaceuticals
FDA approves Pfizer's Tukysa (tucatinib) for maintenance treatment of HER2-positive metastatic breast cancer, offering chemotherapy-free disease control with a median PFS benefit of 8.5 months.
Biotechnology
The 2026 Nobel Prize in Medicine went to the pioneers of optogenetics. With the first optogenetic therapy approaching FDA approval and psychiatric applications in clinical trials, the prize marks a turning point for neuroscience drug development.
Biotechnology
AbbVie and Genmab's epcoritamab (Epkinly) met its primary endpoint in the Phase 3 Epcore DLBCL-2 trial, reducing disease progression or death risk by 51% compared to R-CHOP alone in newly diagnosed DLBCL. This result challenges Roche's Polivy's dominance in the first-line setting.
Biotechnology
Vaxcyte's VAX-31 met all primary endpoints in a pivotal Phase 3 trial against both Pfizer's Prevnar 20 and Merck's Capvaxive. The data are clean, the coverage is broader, and the competitive implications for the adult pneumococcal vaccine market are significant.
Biotechnology
There is a particular kind of deal that tells you something important about where a field is heading. Not the blockbuster acquisition of a late-stage asset, and not the defensive licensing of a competitor's approved drug. The kind that matters is the one where a major pharmaceutical
Pharmaceuticals
Sanofi and Regeneron announce a $1 billion expansion of their immunology alliance to develop next-generation antibodies, signaling confidence in type 2 inflammation biology despite upcoming Dupixent patent expiration.
Pharmaceuticals
A patient death and a trial amendment in Bristol Myers' Phase 3 admilparant program are raising fresh questions about liver toxicity in the LPA1R inhibitor class, just months before a pivotal readout that could reshape the IPF treatment landscape.
Biotechnology
On September 24, 2026, a panel of independent experts advising the FDA voted 7-2 that the probable benefits of Grail's Galleri multicancer early detection blood test outweigh its risks. The panel voted unanimously that the test is safe. It voted 6-4 on effectiveness. And with those
Biotechnology
Viking Therapeutics' VK2735 maintenance dosing data reveal a potential game-changer: patients can maintain 90-97% of weight loss on monthly injections instead of weekly ones. Here's what it means for the obesity drug market.
Get our in depth reports sent directly to your inbox. Unsubscribe anytime.
Eli Lilly's FDA approval of Onswik, a once-weekly basal insulin, marks a significant shift in diabetes management and intensifies competition with Novo Nordisk in the insulin market.
The FDA's approval of AbbVie's Juvmo marks the first selective D1/D5 dopamine receptor agonist for Parkinson's disease, introducing a genuinely new mechanism to a field that has relied on the same pharmacological approach for over 50 years.
Celldex's barzolvolimab met all primary and secondary endpoints in Phase 3 CSU trials, demonstrating complete responses in 42-46% of patients at Week 12 and 45-54% by Week 24—establishing mast cell depletion as a genuine advance in chronic spontaneous urticaria treatment.
Celldex's barzolvolimab Phase 3 data show complete response rates of 42-54% in chronic spontaneous urticaria, including patients who failed omalizumab. Here is what the mechanism means and why it matters.
Alkermes' Phase 1b data for ALKS 7290, an orexin 2 receptor agonist, demonstrates the first clinical evidence that a new mechanism could transform ADHD treatment beyond traditional stimulants.
On September 17, 2026, the FDA approved Fayuvi, the first treatment for Sanfilippo syndrome Type A—at a price of $3.95 million. What does this approval mean for rare disease medicine, access, and the future of gene therapy?
The FDA's approval of Kerendia for type 1 diabetes-associated kidney disease marks the first new treatment option in over 30 years for this underserved patient population.
Vera Therapeutics' ORIGIN 3 Phase 3 trial demonstrates that TRUTAKNA met all prespecified endpoints, achieving eGFR stabilization and a 76% reduction in kidney disease progression risk in IgA nephropathy patients.
The FDA launched its Expedited IND Pilot Program on September 15, 2026, as part of Operation TrialBlazer. The ambition is real, but the delays driving research offshore run deeper than the mechanism being deployed to address them.
Novo Nordisk has rebranded as simply 'Novo.' The name change is the most visible signal yet that the company understands the urgency of its competitive challenge against Eli Lilly in the GLP-1 obesity drug market.
GSK's Jideytro demonstrates a 94% response rate in first-line ROS1-positive NSCLC, with a remarkable 15% complete response rate and 100% intracranial response rate in patients with brain metastases.
Novartis's remibrutinib has achieved what the BTK inhibitor class could not: a Phase 3 win in multiple sclerosis with no liver safety signal. Here's why this matters for the future of MS treatment.
